You are here

Article Text

Article menu
Research letter
The impact of azithromycin therapy on the airway microbiota in asthma
  1. Mariel Slater1,
  2. Damian W Rivett2,
  3. Lisa Williams3,
  4. Matthew Martin3,
  5. Tim Harrison3,
  6. Ian Sayers1,
  7. Kenneth D Bruce4,
  8. Dominick Shaw3
  1. 1Department of Therapeutics and Molecular Medicine, University of Nottingham, Nottingham, UK
  2. 2Department of Ecology and Evolution, Imperial College, London, UK
  3. 3Department of Respiratory Medicine, University of Nottingham, Nottingham, UK
  4. 4Institute of Pharmaceutical Science, Kings College London, London, UK
  1. Correspondence to Dr Kenneth Bruce, King's College London, Molecular Microbiology Research Laboratory, Institute of Pharmaceutical Science, 150 Stamford Street, London SE1 9NH, UK; kenneth.bruce{at}kcl.ac.uk

https://doi.org/10.1136/thoraxjnl-2013-204517

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Introduction

    There is interest in the use of macrolide antibiotics in asthma. Macrolides have been shown to improve airway hyper-responsiveness (AHR) and measures of airway inflammation.1 The degree of AHR may relate to the microbiota present in the airways,2 with a recent study reporting that patients with asthma with a significant improvement in AHR following treatment with clarithromycin had a higher bacterial diversity prior to treatment.3 To our knowledge, the impact on the asthmatic airway microbiota of an antibiotic has not been reported and we therefore set out to establish if macrolide therapy was associated with a change in airway microbiota in asthma.

    Methods

    Five adult patients with moderate/severe asthma (British Thoracic Society step 4–5) (see online supplementary table S1) and no evidence of respiratory infection or bronchiectasis underwent bronchoscopy before and after 6 weeks of daily 250 mg azithromycin therapy. Patients had consented to the study (REC 11/EM/0062). Saline washings of the right upper lobe were obtained following standard procedure, DNA was isolated from the samples (see online supplementary …

    View Full Text

    Supplementary materials

    • Supplementary Data

      This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

      Files in this Data Supplement: